Connect with us
DAPA Banner

Business

Ajanta Pharma, Sun Pharma poised to tap GLP-1 opportunity amid market shift: Siddhartha Khemka

Published

on

Ajanta Pharma, Sun Pharma poised to tap GLP-1 opportunity amid market shift: Siddhartha Khemka
India’s metabolic therapy landscape is undergoing a structural shift following the patent expiry of semaglutide, triggering a rapid transition from a premium, innovator-led market to a highly competitive, volume-driven segment. Historically constrained by high prices and limited access, the category is now witnessing a sharp inflection in demand, supported by significant price erosion of nearly 85–90% and a surge in product launches.

The addressable opportunity remains substantial. With an estimated 75–80 million obese individuals and a large proportion suffering from co-morbid conditions, the need for structured obesity management is becoming increasingly evident. GLP-1 penetration, which remained low due to patent protection, is now expected to rise meaningfully as affordability improves and distribution expands. Over the next 3–5 years, the market could scale to INR34–67 billion, driven by rising patient adoption and chronic therapy demand.

A key growth driver is the expanding prescriber base. While endocrinologists and diabetologists remain primary stakeholders, adoption is increasingly being supported by cardiologists, gastroenterologists, gynaecologists, and other specialists due to the multi-system impact of obesity and metabolic disorders. This broadening ecosystem is expected to accelerate awareness, referrals, and prescription volumes, reinforcing long-term demand visibility.

However, the sector faces structural challenges. The entry of over 10–15 players has intensified competition, leading to rapid market fragmentation and pricing pressures. Despite a large volume opportunity, individual revenue gains are likely to remain modest, with low single-digit contribution to overall sales for most participants. Limited prescription bandwidth—where physicians typically engage with only a handful of brands—further constrains market share potential, increasing the need for aggressive marketing and elevating promotional costs.

Advertisement

Pricing dynamics also reflect a clear stratification, with premium, mid-tier, and mass-market strategies co-existing. While this enhances accessibility, it accelerates commoditisation, weighing on margins across the value chain. Additionally, companies risk diverting focus from established portfolios amid heightened competition in this segment.


An emerging structural trend is the rising preference for next-generation therapies. Even as semaglutide drives awareness and category expansion, newer molecules with superior efficacy are witnessing faster uptake and stronger physician preference, indicating a potential shift in long-term market leadership.
Overall, the GLP-1 segment in India presents a compelling volume-led growth opportunity underpinned by strong demand fundamentals. However, the combination of pricing pressure, intense competition, and limited differentiation suggests that value capture may remain constrained, making scale and execution critical in navigating this evolving landscape.

Ajanta Pharma: Buy| Target Rs 3400

Ajanta Pharma is preparing to launch generic semaglutide post patent expiry of Novo Nordisk’s Ozempic/Wegovy in India, while continuing to expand its portfolio in high-growth segments such as dermatology, pain management, and nephrology. Ajanta Pharma’s long-term growth is driven by its expanding presence in branded generics across India, US, Africa, and Asia, with a focus on chronic therapies and new launches supporting sustained demand and deeper penetration in high-growth markets. Management expects mid-teens revenue growth with EBITDA margins around 27%, supported by expansion in Asia and Africa, a strong US product pipeline, and strategic addition of medical representatives to drive execution.

Sun Pharma: Buy| Target Rs 1940

Sun Pharma’s Innovation momentum remains a key growth pillar, with specialty and novel therapies scaling up meaningfully. USD1b+ innovative sales (ex-milestones) provide resilience against US pricing pressure, while strong domestic formulation execution, consistent market share gains, and ROW/EM stability underpin diversified, sustainable growth drivers. In 3QFY26, SUNP delivered in-line adjusted revenues and EBITDA 6% ahead of estimates, supported by robust DF growth and favorable mix. Margin expansion reflected execution strength, partly offset by continued weakness in US generics due to regulatory headwinds at select sites. We estimate EM+ROW revenues to reach INR230b over FY25-28 at 12% CAGR, while specialty sales grow 11% CAGR to USD1.7b. Sustained DF outperformance, rising innovative R&D intensity, and steady pipeline launches support earnings visibility.

(The author is Siddhartha Khemka, Head of Research – Wealth Management, Motilal Oswal Financial Services)

Advertisement

(Disclaimer: Recommendations, suggestions, views, and opinions given by experts are their own. These do not represent the views of the Economic Times)

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

Pakistan to host regional summit on Monday amid Iran cease-fire talks- report

Published

on


Pakistan to host regional summit on Monday amid Iran cease-fire talks- report

Continue Reading

Business

Whale’s Insight: A Macro-Driven Market With No Safe Haven, And No End To Volatility

Published

on

Whale's Insight: A Macro-Driven Market With No Safe Haven, And No End To Volatility

Stock market activity shows price changes and trading movements in real time

FabrikaCr/iStock via Getty Images

This week, Trump’s flip-flopping triggered three major market reversals in five days as gold, equities, and crypto fell in unison with no safe haven in sight. Multiple scenarios are taking shape depending on how long the Hormuz closure lasts

Continue Reading

Business

Rentomojo IPO: Furniture e-marketplace files DRHP with Sebi; to raise Rs 150 crore from fresh issue

Published

on

Rentomojo IPO: Furniture e-marketplace files DRHP with Sebi; to raise Rs 150 crore from fresh issue
E-marketplace Rentomojo Limited has filed a Draft Red Herring Prospectus (DRHP) with the Securities and Exchange Board of India (Sebi) to launch its initial public offering (IPO). The company plans to raise Rs 150 crore via the issue of fresh equity.

The public offer will be a mix of issuing fresh shares and an offer for sale (OFS) where existing shareholders will offload up to 28,399,567 equity shares.

About Rentomojo

Rentomojo is an online rental and subscription platform for home furniture and appliances. Its promoter is Geetansh Bamania.The company operates a technology-driven, full-stack direct-to-consumer (D2C) online rental and subscription platform for furniture and home appliances in India. The DRHP claims that the company is a market leader in this segment with an estimated 42%–47% share in the organised home furniture and appliances rental segment (excluding water purifiers) based on subscription revenue in the fiscal of 2025, with 2,27,511 live subscribers across 22 cities as of September 30, 2025, supported by a scaled service network that includes 21 warehouses and approximately 444,486 sq. ft. of warehousing space.

Advertisement

The company quoted a Redseer report to back its claims.
It operates an omni-channel platform comprising its online interface and 67 experience stores across India (as of September 30, 2025), offering flexible subscription access to furniture and appliances across a portfolio of 728,773 live products.
Also read: IPO Calendar: No fresh issues next week; Coal India subsidiary, 6 more companies set to debut

Rentomojo financials

The company’s revenue from operations stood at Rs 176.61 crore for the six months ended September 30, 2025, and Rs 266 crore for fiscal 2025, while restated profit after tax was at Rs 61.38 crore for the six months ended September 30, 2025 and Rs 43.11 crore for FY25.

IPO proceeds

The company has proposed to utilise the net proceeds from the initial public offer for multiple purposes, including the repayment or prepayment, in full or in part, of certain outstanding borrowings along with the accrued interest thereon availed by the company; the payment of lease rentals or license fees for its warehouses and experience stores (referred to as the “Premises”); and general corporate purposes.

Following its IPO, the stock will be listed on the NSE and BSE.

Lead managers

Motilal Oswal Investment Advisors Limited, Axis Capital Limited, and IIFL Capital Services Limited (formerly known as IIFL Securities Limited) are the Book Running Lead Managers to the issue.

Advertisement

(Disclaimer: The recommendations, suggestions, views, and opinions given by the experts are their own. These do not represent the views of The Economic Times.)

Continue Reading

Business

Charts signal more pain ahead for Nifty; select stocks still offer tactical opportunities: Nagaraj Shetti

Published

on

Charts signal more pain ahead for Nifty; select stocks still offer tactical opportunities: Nagaraj Shetti
With volatility on the rise and a truncated trading week ahead, market participants are closely watching technical signals for direction. While global cues and macro uncertainties remain fluid, charts indicate that the Nifty may continue to face downward pressure in the near term.

Technical analyst Nagaraj Shetti from HDFC Securities believes the trend remains firmly bearish.

“No doubt market is in a downtrend. Every rise is being sold. Lower tops and bottoms over the past month indicate bears are in control. The recent bounce near 23,400–23,500 has formed a lower top. Nifty could break 22,450 next week and slide towards 22,000 in the coming weeks.”

Advertisement

Weak Supports Amid Global Pressure

Despite intermittent recoveries, the underlying weakness persists, with global factors weighing heavily on sentiment.

“I do not think stability will come soon. Markets are echoing global pressure—rupee and crude are key concerns. The 22,450 level is just a psychological support. Given the bearish pattern, we could soon break below this level.”

Coal India Shows Relative Strength


Even in a falling market, some stocks are holding up better than the benchmark.“Coal India has corrected, but the trend remains positive with higher tops and bottoms. Around 430–435 is strong support. The stock could bounce back towards 475–480 in the near term.”

Advertisement

Stock Strategy: Buy Strength, Sell Weakness


Shetti suggests a balanced approach with opportunities on both sides of the market.

“Ather Energy is in a strong uptrend with consistent higher tops and bottoms. It has broken key resistance near 750–760. One can buy around current levels for a target of 850, with a stop loss at 760.”

“On the short side, BDL is weak with a clear bearish pattern. One can sell around current levels for a target of 1070, keeping a stop loss at 1160.”

Advertisement

Outlook


With multiple expiries and limited trading sessions ahead, volatility is likely to remain high. While selective stocks may outperform, the broader market trend continues to favour caution, with charts pointing towards further downside in the Nifty.

Continue Reading

Business

China’s Moonshot AI Seeks Listing in Hong Kong Under Heightened Scrutiny

Published

on

China’s Moonshot AI Seeks Listing in Hong Kong Under Heightened Scrutiny

Moonshot AI, one of China’s most promising artificial-intelligence startups, is considering changing its corporate structure to pave the way for an initial public offering in Hong Kong, people familiar with the matter said.

The company is raising a new round of private funding that would value it at around $18 billion, some of the people said. A previous round of fundraising from global investors in December had valued the company around $4.3 billion.

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Continue Reading

Business

Tech Investing Seems Broken. Our Roundtable Pros Share 15 Stock Picks to Fix Your Portfolio.

Published

on

Tech Investing Seems Broken. Our Roundtable Pros Share 15 Stock Picks to Fix Your Portfolio.

Tech Investing Seems Broken. Our Roundtable Pros Share 15 Stock Picks to Fix Your Portfolio.

Continue Reading

Business

Free prom hire boutique set up for two schools

Published

on

Free prom hire boutique set up for two schools

Mia, a student, says it will lesson the burden on anyone spending hundreds of pounds on a dress.

Continue Reading

Business

Service charges coming under government scrutiny

Published

on

Service charges coming under government scrutiny

People across the West explain how the charges on their buildings are affecting their finances.

Continue Reading

Business

Are you questioning ‘mutual fund sahi hai’ after 10% portfolio loss? Expert explains bigger picture

Published

on

Are you questioning ‘mutual fund sahi hai’ after 10% portfolio loss? Expert explains bigger picture
Recent market volatility has left many mutual fund investors questioning their decisions, especially those who started investing over the past couple of years. With portfolios slipping into losses and returns looking unimpressive in the short term, a common doubt is emerging—kya mutual fund sahi hai?

A query from Lari, a government teacher from Madhya Pradesh and a viewer of The Money Show on ET Now, reflects this sentiment. She says her mutual fund portfolio is down nearly 10% and she is struggling to see any benefit so far while investing in mutual funds.

Also Read | Equity mutual funds lose up to 48% on SIP investments in FY26. Have you added any to your portfolio?

According to financial expert Harshvardhan Roongta, this is a very common concern, particularly among new investors. Those who have entered the market in the last one or two years may even see negative returns in their SIP investments, leading to doubts about whether they made the right choice. Naturally, many begin comparing mutual funds with fixed deposits, wondering if a steady 6% return would have been a better option.

“So, you might question yourself thinking whether you have done the right thing because the common comparison that investors would have if after two years or three years they see their portfolio negative the first thing that comes to their mind is that it would be better if I put my money in fixed deposit, at least I would have got 6% per annum. So, these are the things that usually investors are definitely confused with,” the expert said.

Advertisement

However, this comparison often overlooks a key aspect—mutual funds, especially equity funds, are market-linked instruments. Their performance is directly influenced by broader economic conditions, global events, and investor sentiment. When there is uncertainty—be it geopolitical tensions, economic stress, or global disruptions—markets tend to fall, and mutual fund returns reflect that reality.
“Markets will fall when there is uncertainty and they will go up when there is clarity,” the expert further highlighted.
Roongta explains that this behaviour is not a flaw but a feature of how markets function. In fact, it would be more concerning if markets continued to rise despite significant global stress, as that would indicate a disconnect from underlying realities. Market corrections are a natural response to uncertainty, and they help bring valuations in line with fundamentals.
The expert said that, “The question is what actually would be a cause of concern would be that there is war that is going on right now as it is and there is so much of stress on fuel, energy; there is so much of concerns about security and the war escalating, etc, and markets ignored all this and continuously just kept going one way upwards, that would be a cause of concern because it is not doing what it is supposed to do.”

Over time, as clarity returns and economic conditions improve, markets tend to recover. However, this recovery is not immediate. Even if external risks such as geopolitical tensions ease, the real driver of sustained market growth—corporate earnings—takes time to improve. As companies report better performance and the economy stabilises, returns gradually follow.

Also Read | Sebi simplifies gifting of mutual funds. Here’s what it means for investors

This highlights an important lesson for investors: equity investing requires patience and a long-term perspective. Short-term volatility is inevitable, and expecting consistent positive returns over one- or two-year periods can lead to disappointment.

At the same time, not every investor may be comfortable with this level of uncertainty. Roongta emphasises that before investing in mutual funds, especially equity schemes, it is essential to understand how they work, what kind of returns to expect, and the risks involved in the short term. Investors who are uncomfortable with market fluctuations may be better suited to more stable options like fixed deposits or other low-risk instruments.

Ultimately, the decision comes down to alignment. If an investor understands the nature of market-linked investments and is willing to stay invested through cycles, mutual funds can be an effective wealth creation tool. But if volatility causes stress and uncertainty, it may be worth reconsidering the investment approach to ensure both financial and emotional comfort.

Advertisement

In volatile times, the real question is not whether mutual funds are “right” or “wrong”—but whether they are the right fit for your expectations and investment temperament.

Add ET Logo as a Reliable and Trusted News Source

Continue Reading

Business

Hua Medicine (Shanghai) Ltd. 2025 Q4 – Results – Earnings Call Presentation (OTCMKTS:HUMDF) 2026-03-28

Published

on

OneWater Marine Inc. (ONEW) Q1 2026 Earnings Call Transcript

This article was written by

Seeking Alpha’s transcripts team is responsible for the development of all of our transcript-related projects. We currently publish thousands of quarterly earnings calls per quarter on our site and are continuing to grow and expand our coverage. The purpose of this profile is to allow us to share with our readers new transcript-related developments. Thanks, SA Transcripts Team

Continue Reading

Trending

Copyright © 2025